Document is current
Any future updates will be listed below
-
Authors
McShan, Andrew C. https://orcid.org/0000-0002-3212-9867
Devlin, Christine A. https://orcid.org/0000-0002-8541-7432
Papadaki, Georgia F.
Sun, Yi
Green, Adam I. https://orcid.org/0000-0002-7397-6579
Morozov, Giora I.
Burslem, George M. https://orcid.org/0000-0002-2812-983X
Procko, Erik https://orcid.org/0000-0002-0028-490X
Sgourakis, Nikolaos G. https://orcid.org/0000-0003-3655-3902
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (5R01AI143997, 5R01AI143997)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM142505, 5R35GM125034, 3R35GM125034-05S)
- License Information
-
More Information
Article History
Received: 25 October 2021
Accepted: 28 April 2022
First Online: 20 June 2022
Competing interests
: E.P. is an employee of Cyrus Biotechnology. N.G.S. is a cofounder of Tantigen Bio, Inc., MultiplexThera, Inc. and a named inventor on patents concerning the preparation of ligand-receptive MHC-I and MHC-like molecules; all companies had no role in this study. The other authors declare no competing interests.
